Parkinson disease Cell Models for Research

Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 1% of individuals over 60 years old. According to the World Health Organization (WHO), the global prevalence has doubled over the past 25 years, with over 8.5 million cases reported in 2019. The incidence increases with age, and men are 1.5 times more likely to develop PD than women. The disease leads to progressive motor symptoms (bradykinesia, rigidity, tremor) and non-motor symptoms (cognitive impairment, depression, sleep disorders), significantly impacting quality of life. There is no cure, and current therapies only manage symptoms. The economic burden is substantial, with direct and indirect costs estimated at $52 billion annually in the United States alone (Parkinson's Foundation). Research is critical to understand disease mechanisms and develop disease-modifying therapies.

PD is an ideal model for studying neurodegeneration due to its well-characterized pathology, including the loss of dopaminergic neurons in the substantia nigra and the accumulation of alpha-synuclein aggregates (Lewy bodies). The disease has both sporadic and familial forms, with several genes identified (SNCA, LRRK2, PARKIN, PINK1, DJ-1). Public datasets, such as the Parkinson's Progression Markers Initiative (PPMI) and the GEO repository, provide extensive omics data. Open questions include the precise mechanisms of alpha-synuclein toxicity, the role of mitochondrial dysfunction, and the interplay between genetic and environmental factors. Gene-edited cell models enable functional studies of these genes in human neuronal contexts, providing valuable tools for drug discovery and mechanistic research.

Several pathways contribute to PD pathogenesis:

1. Alpha-synuclein aggregation and proteostasis: Misfolding and aggregation of alpha-synuclein (SNCA) leads to neurotoxicity. Impairment of the ubiquitin-proteasome system and autophagy-lysosomal pathway exacerbates accumulation.

2. Mitochondrial dysfunction: Defects in mitochondrial complex I activity, increased reactive oxygen species (ROS), and impaired mitophagy (PINK1/Parkin pathway) lead to neuronal death.

3. Neuroinflammation: Microglial activation and release of pro-inflammatory cytokines contribute to neurodegeneration.

4. Oxidative stress: Imbalance between ROS production and antioxidant defenses causes cellular damage.

5. Impaired protein trafficking and synaptic dysfunction: Mutations in LRRK2 and other genes disrupt vesicle trafficking and synaptic transmission.

Data from NCBI Gene, ClinVar, and COSMIC.

Key signaling networks implicated in PD include:

• • PI3K/AKT/mTOR pathway: Regulates cell survival and autophagy. Dysregulation leads to impaired proteostasis.
• • MAPK/ERK pathway: Involved in oxidative stress response and neuroinflammation.
• • Wnt/β-catenin pathway: Plays a role in dopaminergic neuron development and survival.
• • NF-κB pathway: Mediates neuroinflammation.
• • Autophagy-lysosomal pathway: Critical for clearance of protein aggregates; mutations in LRRK2 and GBA impair this process.
• • Mitochondrial quality control: PINK1/Parkin-mediated mitophagy is essential for removing damaged mitochondria.

Organoids recapitulate 3D tissue architecture and cell-cell interactions, providing a more physiologically relevant model than 2D cultures.

• • Neurotoxin-induced models: Administration of MPTP, 6-OHDA, or rotenone to rodents induces dopaminergic neuron loss.
• • Genetic models: Transgenic mice overexpressing human SNCA (A53T) or carrying LRRK2 mutations (G2019S) recapitulate some PD features.
• • Viral vector models: Injection of adeno-associated viruses (AAV) carrying alpha-synuclein or other genes into the substantia nigra.
• • PDX (Patient-Derived Xenograft) models: Not commonly used for PD, but xenografts of patient-derived cells can be used for studying tumor-related aspects (e.g., in cases of co-morbidity).

CRISPR-Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications. For PD, common models include:

• • SNCA knockout cell lines: Ablation of alpha-synuclein to study its normal function and toxicity.
• • SNCA A53T knock-in cell lines: Introduction of the pathogenic mutation to model aggregation.
• • LRRK2 G2019S knock-in cell lines: Expression of the most common PD mutation to study kinase activity and downstream effects.
• • PINK1 knockout cell lines: Loss of function to model mitochondrial dysfunction.
• • PARKIN knockout cell lines: Impaired mitophagy.

These gene-edited models are sequence-verified and commercially available from various sources, providing reproducible and physiologically relevant tools for drug discovery and functional genomics. They allow researchers to study disease mechanisms in human neuronal cells without the confounding factors of patient-to-patient variability.

Gene-edited cell lines are essential for validating the function of PD-associated genes. For example:

• • Knockout of PINK1 in SH-SY5Y cells leads to mitochondrial dysfunction, as measured by decreased ATP production and increased ROS.
• • Knock-in of LRRK2 G2019S in iPSC-derived dopaminergic neurons recapitulates neurite outgrowth defects and altered autophagy.
• • SNCA knockout in LUHMES cells reduces alpha-synuclein aggregation and improves cell survival under stress.

These models enable high-throughput screening to identify genetic modifiers and therapeutic targets.

Isogenic pairs (e.g., wild-type vs. LRRK2 G2019S knock-in) are used to screen compounds that selectively inhibit mutant kinase activity. For example, LRRK2 kinase inhibitors are tested for their ability to rescue neurite outgrowth defects in mutant cells. Similarly, SNCA A53T knock-in cells are used to screen for compounds that reduce alpha-synuclein aggregation. These models also help study resistance mechanisms, such as compensatory pathways that may limit drug efficacy.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, are lethal only in the context of a specific PD mutation. For example, in LRRK2 G2019S cells, silencing of certain autophagy-related genes may cause cell death, revealing potential therapeutic targets. Gene-edited models also enable the identification of secreted biomarkers (e.g., alpha-synuclein levels) that can be measured in culture media and translated to clinical diagnostics.